Verition Fund Management
PTGX icon

Verition Fund Management’s Protagonist Therapeutics PTGX Stock Holding History

Verition Fund Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,000
Closed -$3.14M – 3285
2025
Q4 		$3.14M Buy
+36,000
New +$2.95M 0.01% 1210

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Verition Fund Management's PTGX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 10,143 shares worth $1.24M. The stake represents 0.01% of the portfolio and ranks #1343 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in PTGX as recently as Q4 2025.

Verition Fund Management first reported a position in PTGX in Q2 2023 and has held it in 6 quarters since. The position peaked at $2.34M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Verition Fund Management held 10,143 shares of Protagonist Therapeutics worth $1.24M as of Q2 2026.
  • Protagonist Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1343 holding.
  • Verition Fund Management first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • Verition Fund Management's Protagonist Therapeutics position peaked at $2.34M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.